Soluble donor HLA class I and beta 2m-free heavy chain in serum of lung transplant recipients: steady-state levels and increases in patients with recurrent CMV infection, acute rejection episodes, and poor outcome.
We determined the concentration of donor sHLA/beta(2)m and total beta(2)m-free heavy chain (HC) in the serum of lung transplant recipients with ELISA assays. While we were unable to detect specific donor beta(2)m-free HCs due to a lack of available antibodies, we could determine if events that led to an increase in the release of beta(2)m-free HC also led to an increase in the release of donor sHLA/beta(2)m, particularly the 36 kDa, proteolytically cleaved form. We found that lung transplants constituitively release donor sHLA/beta(2)m at ng/ml levels. The levels (both of donor sHLA/beta(2)m and total beta(2)m-free HC) were significantly increased in CMV-sero-negative recipients (but not in CMV-sero-positive recipients) at the onset of post-transplant CMV disease. Acute rejection episodes were also associated with an increased release of donor sHLA/beta(2)m, but not of beta(2)m-free HC. However, in patients with particularly poor outcome (i.e., graft loss within 1 year) there was a significant release of beta(2)m-free HC. Analysis of one such patient showed a predominance of 36 kDa forms of donor-sHLA/beta(2)m. Our data are consistent with the hypothesis that the metalloproteinase that cleaves beta(2)m-free HC is active during uncontrolled CMV infection and acute rejection. However, recall responses to CMV and controlled immune responses to donor may result in little or no activation of sHLA class I release.
DeVito-Haynes
L D
LD
Department of Surgery, University of Wisconsin, Madison, Wisconsin 53792, USA. haynes@surgery.wisc.edu
Jankowska-Gan
E
E
Meyer
K C
KC
Cornwell
R D
RD
Zeevi
A
A
Griffith
B
B
Dauber
J
J
Iacono
A
A
Burlingham
W J
WJ
Love
R B
RB
D000208:Acute Disease; D015153:Blotting, Western; D001989:Bronchiolitis Obliterans / Q000276:immunology; D003586:Cytomegalovirus Infections / Q000097:blood / Q000276:immunology*; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000097:blood / Q000276:immunology*; D006680:HLA Antigens / Q000032:analysis / Q000097:blood*; D015395:Histocompatibility Antigens Class I / Q000032:analysis / Q000097:blood*; D006801:Humans; D007700:Kinetics; D008168:Lung / Q000276:immunology / Q000378:metabolism; D016040:Lung Transplantation / Q000009:adverse effects / Q000276:immunology*; D012008:Recurrence; D012995:Solubility; D013577:Syndrome; D014019:Tissue Donors; D016896:Treatment Outcome; D001613:beta 2-Microglobulin / Q000032:analysis / Q000097:blood / Q000378:metabolism
D006680:HLA Antigens; D015395:Histocompatibility Antigens Class I; D001613:beta 2-Microglobulin